Every 10-Q that ARCO BIOMEDICAL CO LTD (ACBM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACBM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACBM filings page.
Acro Biomedical Co., Ltd. reported no revenue for the three and six months ended June 30, 2026, continuing a multi‑year trend of no sales since December 31, 2022. For the six‑month period, operating expenses were $77,825, primarily general and administrative and public company costs, leading to a net loss of $65,130 versus $25,863 a year earlier.
Cash was only $3,648 and current liabilities were $448,437, resulting in a stockholders’ deficit of $444,789. The company’s auditor and management state that these conditions, along with the absence of revenue and product output, raise substantial doubt about its ability to continue as a going concern. Operations are being funded almost entirely by a minority stockholder, to whom $384,287 is owed.
The company has no full‑time employees; its sole officer serves part‑time without pay. Management reports material weaknesses in internal control, including lack of segregation of duties and reliance on consultants. The common stock trades on the OTC Pink Limited Market on an unsolicited‑only basis, with no market makers and limited liquidity.
Acro Biomedical Co., Ltd. reported another loss-making, non‑revenue quarter for Q1 2026. The company generated no revenue and recorded a net loss of $43,774, driven by selling, general and administrative expenses of $60,271. Results included a $20,000 gain from liability extinguishment and $3,503 of imputed related‑party interest.
Cash was only $3,873 at March 31, 2026, against current liabilities of $431,108, leaving a working capital deficit of $427,235 and total stockholders’ deficit of $427,235. The company depends on a minority stockholder, who advanced $49,596 in the quarter and was owed $374,008, with total related‑party payables of $375,108.
Management and the auditor highlight substantial doubt about Acro Biomedical’s ability to continue as a going concern, citing minimal cash, no revenue since 2022, recurring losses and stockholders’ deficit. Operations are extremely limited, there are no current product orders, and internal controls and disclosure controls are considered ineffective due to material weaknesses.
ACRO Biomedical (ACBM) filed its quarterly report for the period ended September 30, 2025. The company reported no revenue, a Q3 net loss of $117,809, and a nine‑month net loss of $143,672. Operating expenses were $115,099 in Q3 and $137,647 year‑to‑date, primarily for public company costs. Interest expense to related parties was $2,710 in Q3 and $6,025 year‑to‑date. Loss per share remained $(0.00) basic and diluted.
The balance sheet shows cash $4,323, total assets $4,323, current liabilities $436,942 (including due to related parties $300,360 and deferred revenue $20,000), and a stockholders’ deficit of $(432,619). Operating cash outflow was $(170,925), funded by $174,772 in advances from a minority stockholder. Management discloses substantial doubt about continuing as a going concern given no revenue since December 31, 2022, OTC Pink Limited Market trading with no market makers, and reliance on related‑party funding. The Hong Kong storage lease was terminated on August 30, 2025, with a $2,285 deposit returned. Shares outstanding were 60,042,000 as of November 10, 2025. Disclosure controls were deemed ineffective due to material weaknesses.